TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29782824

Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers
Number of subjects: 298

Group type: COMPARATOR
Intervention: Non-APOE-ε4 carriers
Number of subjects: 298
Study: 29783928

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (4 sessions of supervised physical activity and a home-based exercise program)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 226
Study: 29784042

Group type: EXPERIMENTAL
Intervention: Neoadjuvant oxaliplatin and capecitabine (XELOX) combined with bevacizumab plus radiotherapy
Number of subjects: 45
Study: 29784059

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) using a low-energy diet (LED) meal replacement approach combined with physical activity
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual medical care (UMC)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 138
Study: 29784469

Group type: EXPERIMENTAL
Intervention: Full dose (27,476 IU)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Tapered doses (10,447 IU, 3013 IU, 587 IU)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Tapered doses (158 IU, 31 IU)
Number of subjects: 318
Study: 29784633

Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy and optical coherence tomography
Number of subjects: 14
Study: 29784635

Group type: EXPERIMENTAL
Intervention: Mobile phone with diabetes diary app and additional health counseling by telephone calls from a diabetes specialist nurse (n=50)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Mobile phone with diabetes diary app (n=51)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 101
Study: 29784747

Group type: EXPERIMENTAL
Intervention: Radiotherapy for uveal melanoma based on tumor size
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with immunotherapies for cutaneous melanoma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second-line treatment in metastatic melanoma
Number of subjects: 0
Study: 29785141

Group type: EXPERIMENTAL
Intervention: Self-screening method for cardiovascular risk assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard screening method for cardiovascular risk assessment
Number of subjects: 0
Study: 29785275

Group type: EXPERIMENTAL
Intervention: Maternal knowledge about correct infant sleep position (back)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Compliance with expert recommendations for infant sleep
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Odds of meeting sleep duration recommendations
Number of subjects: 54
Study: 29785301

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2.0 mg every 4 weeks (2q4)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8)
Number of subjects: 862

Group type: COMPARATOR
Intervention: Laser control treatment
Number of subjects: 862
Study: 29785458

Group type: EXPERIMENTAL
Intervention: High-resolution standardized laparoscopic cholecystectomy protocol (HRSL)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (pre-intervention)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (post-intervention)
Number of subjects: 39
Study: 29785473

Group type: EXPERIMENTAL
Intervention: Endogenous melatonin levels preoperatively compared to intraoperative and postoperative levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plasma melatonin levels correlation with postoperative morphine consumption
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preoperative cortisol levels compared to intraoperative and postoperative levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Body temperatures across all measurement periods
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Changes in endogenous melatonin levels and morphine consumption
Number of subjects: 30
Study: 29785539

Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg single dose
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 29785709

Group type: EXPERIMENTAL
Intervention: Ibrutinib with rituximab (IR)
Number of subjects: 50
Study: 29786762

Group type: EXPERIMENTAL
Intervention: Patients cared by family/proxies or community nurses
Number of subjects: 26853

Group type: COMPARATOR
Intervention: Patients living in homes
Number of subjects: 26853

Group type: EXPERIMENTAL
Intervention: Patients over 80 years of age
Number of subjects: 26853

Group type: EXPERIMENTAL
Intervention: Patients over 90 years of age
Number of subjects: 26853

Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 26853
Study: 29787575

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (IV tPA)
Number of subjects: 20
Study: 29787734

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) including specific diaphragm techniques
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham diaphragm intervention
Number of subjects: 66
Study: 29788155

Group type: EXPERIMENTAL
Intervention: GDC-0575 and gemcitabine (1000 mg/m2 or 500 mg/m2)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: GDC-0575 monotherapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: GDC-0575 and gemcitabine
Number of subjects: 102
Study: 29788339

Group type: EXPERIMENTAL
Intervention: Cold chain capacity of -60°C or colder for the STRIVE Ebola vaccine trial
Number of subjects: 0
Study: 29788340

Group type: EXPERIMENTAL
Intervention: Utilizing nurses to staff the clinical trial for the Ebola vaccine.
Number of subjects: 0
Study: 29788341

Group type: EXPERIMENTAL
Intervention: STRIVE intervention during the Ebola outbreak
Number of subjects: 0
Study: 29788342

Group type: EXPERIMENTAL
Intervention: Vaccine against Ebola
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29788343

Group type: EXPERIMENTAL
Intervention: Immediate vaccination with rVSV∆G-ZEBOV-GP vaccine (within 7 days)
Number of subjects: 8600

Group type: COMPARATOR
Intervention: Deferred vaccination (within 18-24 weeks)
Number of subjects: 8600
Study: 29788345

Group type: EXPERIMENTAL
Intervention: rVSV∆G-ZEBOV-GP Vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29788346

Group type: EXPERIMENTAL
Intervention: Ebola vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29788347

Group type: EXPERIMENTAL
Intervention: Vaccine intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (if applicable)
Number of subjects: 0
Study: 29788348

Group type: EXPERIMENTAL
Intervention: Vaccine against Ebola
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or no vaccine)
Number of subjects: 0
Study: 29788349

Group type: EXPERIMENTAL
Intervention: Vaccine against Ebola
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29788444

Group type: EXPERIMENTAL
Intervention: Lower urinary norepinephrine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower free T4
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower CIBA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Higher urinary norepinephrine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Higher free T4
Number of subjects: 12
Study: 29788497

Group type: EXPERIMENTAL
Intervention: GSK2256098 (1000 mg, 750 mg, 500 mg; dosed twice daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: GSK2256098 (PET substudy)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: GSK2256098
Number of subjects: 13
Study: 29788694

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg twice daily for first 3 weeks, followed by 20 mg once daily for 6 months
Number of subjects: 124
Study: 29788910

Group type: EXPERIMENTAL
Intervention: Wound infection (verified by positive culture)
Number of subjects: 457
Study: 29788919

Group type: EXPERIMENTAL
Intervention: PiCCOplus (SVV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Functional hemodynamic parameters (except for PVI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PVI
Number of subjects: 30
Study: 29788942

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell (BMC) implantation
Number of subjects: 33
Study: 29788998

Group type: EXPERIMENTAL
Intervention: Self-report depression screening tool (9-item Patient Health Questionnaire - PHQ-9)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Culturally adapted stigma measures
Number of subjects: 319
Study: 29789017

Group type: EXPERIMENTAL
Intervention: CBT worksheets completed on paper forms
Number of subjects: 0

Group type: COMPARATOR
Intervention: CBT worksheets completed on a mobile application (app)
Number of subjects: 0
Study: 29789029

Group type: EXPERIMENTAL
Intervention: Structural neuroimaging studies in Down syndrome (DS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortical lobar effect sizes from early childhood through adolescence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frontal GM volume in Down syndrome
Number of subjects: 0
Study: 29789238

Group type: EXPERIMENTAL
Intervention: LD-TDV administered by PharmaJet
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Simultaneous injection of two LD-TDV doses
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: LD-TDV (one or two doses)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: LD-TDV (two doses given either concomitantly or 90 days apart)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: LD-TDV (overall safety assessment)
Number of subjects: 67
Study: 29789277

Group type: EXPERIMENTAL
Intervention: Web-based perioperative exercise program (iPEP study)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Web-based intervention for hepatic inflammation and physical performance (HELP study)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Web-based exercise for depression (EXDEP study)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Web-based mentoring for microbiome, exercise, and diet (COMMED study)
Number of subjects: 20
Study: 29789395

Group type: EXPERIMENTAL
Intervention: SBP <140 mm Hg achieved within 2 hours (reduced and maintained)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: SBP <140 mm Hg achieved within 2 hours (reduced but not maintained)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Subjects without reduction of SBP <140 mm Hg within 2 hours
Number of subjects: 1000
Study: 29789639

Group type: EXPERIMENTAL
Intervention: Fludarabine as part of the lymphodepleting chemotherapy regimen prior to ACT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fludarabine in the preconditioning regimen
Number of subjects: 0
Study: 29789971

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) program
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Restriction of intravenous fluid element
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Surgery during the early study period
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Postoperative morbidity
Number of subjects: 168
Study: 29790103

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (30, 50 or 70 mg/day)
Number of subjects: 314
Study: 29790125

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions for the management of bleeding (fluid replacement, red blood cells transfusion, prothrombin complex concentrates, antifibrinolytic drugs, idarucizumab)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Management of bleeding patients
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Management of bleeding complications in patients treated with DOACs
Number of subjects: 117
Study: 29792074

Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT) including tinnitus-specific educational counseling and sound therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 29792535

Group type: EXPERIMENTAL
Intervention: Veliparib (PARP inhibitor) combined with topotecan
Number of subjects: 60
Study: 29792726

Group type: EXPERIMENTAL
Intervention: Anxious youth
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy youth
Number of subjects: 31
Study: 29793397

Group type: EXPERIMENTAL
Intervention: FOCUS (smartphone-delivered intervention)
Number of subjects: 163

Group type: COMPARATOR
Intervention: WRAP (clinic-based group intervention)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: FOCUS
Number of subjects: 163

Group type: COMPARATOR
Intervention: WRAP
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 163
Study: 29793553

Group type: EXPERIMENTAL
Intervention: World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School Mental Health Manual-based intervention in three 6-h, face-to-face sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group (not receiving training during the study period)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School Mental Health Manual-based intervention
Number of subjects: 0
Study: 29793587

Group type: EXPERIMENTAL
Intervention: Cefazolin 4 g dose administered before surgery
Number of subjects: 116
Study: 29793590

Group type: EXPERIMENTAL
Intervention: Medical autopsy and virtual autopsy (Group M/V)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Virtual autopsy only (Group V)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Medical and virtual autopsy (Group M/V)
Number of subjects: 162
Study: 29793604

Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 20
Study: 29794066

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day and octreotide 30 mg every 28 days
Number of subjects: 43
Study: 29794089

Group type: EXPERIMENTAL
Intervention: Interventional treatment
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Craniotomy
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Interventional therapy
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Craniotomy clipping
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Interventional treatment and Craniotomy
Number of subjects: 1500
Study: 29794101

Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis, endovascular treatment or both
Number of subjects: 140
Study: 29795625

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 4549

Group type: EXPERIMENTAL
Intervention: Chlamydia during pregnancy
Number of subjects: 4549

Group type: EXPERIMENTAL
Intervention: Gonorrhea during pregnancy
Number of subjects: 4549

Group type: EXPERIMENTAL
Intervention: Trichomoniasis during pregnancy
Number of subjects: 4549

Group type: EXPERIMENTAL
Intervention: HIV during pregnancy
Number of subjects: 4549

Group type: EXPERIMENTAL
Intervention: Overall STI incidence during pregnancy
Number of subjects: 4549
Study: 29796289

Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 0
Study: 29796622

Group type: EXPERIMENTAL
Intervention: 200 IU or 2000 IU vitamin D3/d
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplement intake >872 IU/d
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Gestational age and 25(OH)D concentration
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 25(OH)D concentration <13 ng/mL
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard prenatal supplementation
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Mean serum 1,25(OH)2D
Number of subjects: 78
Study: 29796648

Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training (RET) for 12 weeks (60-75% 1-repetition maximum)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Essential Amino Acids (EAA) ingestion (6.8 g)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: RET
Number of subjects: 19
Study: 29796652

Group type: EXPERIMENTAL
Intervention: Hydrocephalus or contrast-enhancing ventricles
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Parenchymal images (abscesses, nodules, or white matter images)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Parenchymal images
Number of subjects: 71
Study: 29796775

Group type: EXPERIMENTAL
Intervention: Nocturia involving ≥ 2 nocturnal voids
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: Comorbid conditions and lower urinary tract symptoms (LUTS)
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: Female sex, age > 60 years, diabetes, cardiac disease, body mass index, IPSS voiding score, stress urinary incontinence, wet OAB, HADS anxiety score
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 8284

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 8284
Study: 29797054

Group type: EXPERIMENTAL
Intervention: Fabry-specific stroke risk score
Number of subjects: 159

Group type: COMPARATOR
Intervention: CHA score
Number of subjects: 159
Study: 29797069

Group type: EXPERIMENTAL
Intervention: Quantitative computed tomography (QCT) imaging measurement of airway wall thickness (WAP)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Periodic spirometries
Number of subjects: 799

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 799
Study: 29797559

Group type: EXPERIMENTAL
Intervention: SleepEE
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: TDEE
Number of subjects: 72
Study: 29797583

Group type: EXPERIMENTAL
Intervention: ONCOS-102 (AdV5/3-D24-GM-CSF)
Number of subjects: 0
Study: 29797706

Group type: EXPERIMENTAL
Intervention: CPR performed by EMS according to European Resuscitation Council Resuscitation Guidelines (2010)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: CPR-related injuries
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Older age, male gender, and public location
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Duration of CPR attempts
Number of subjects: 149
Study: 29797710

Group type: EXPERIMENTAL
Intervention: Pre-operative sepsis
Number of subjects: 1894

Group type: COMPARATOR
Intervention: No pre-operative sepsis
Number of subjects: 1894
Study: 29798770

Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-coated balloon treatment
Number of subjects: 1406
Study: 29798831

Group type: EXPERIMENTAL
Intervention: Web-based transdiagnostic intervention (10 weeks, based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Web-based transdiagnostic intervention
Number of subjects: 105

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 105
Study: 29799100

Group type: EXPERIMENTAL
Intervention: Subcutaneous semaglutide (1.5 mg supratherapeutic dose)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 29799329

Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 0
Study: 29799545

Group type: EXPERIMENTAL
Intervention: Enteral glutamine 0.5 g/kg/day
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Isocaloric maltodextran control
Number of subjects: 2700
Study: 29799874

Group type: EXPERIMENTAL
Intervention: Circulating complement-activating anti-HLA DSAs
Number of subjects: 7936
Study: 29799915

Group type: EXPERIMENTAL
Intervention: Timolol eyedrops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo or alternative treatment not specified)
Number of subjects: 0
Study: 29800033

Group type: EXPERIMENTAL
Intervention: Airway transplantation using human cryopreserved aortic allograft with custom-made stent
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Airway transplantation
Number of subjects: 20
Study: 29800181

Group type: EXPERIMENTAL
Intervention: High-intensity imaging surveillance (mean of 2.9 scans)
Number of subjects: 8529

Group type: COMPARATOR
Intervention: Low-intensity imaging surveillance (mean of 1.6 scans)
Number of subjects: 8529

Group type: EXPERIMENTAL
Intervention: High-intensity CEA testing (mean of 4.3 tests)
Number of subjects: 8529

Group type: COMPARATOR
Intervention: Low-intensity CEA testing (mean of 1.6 tests)
Number of subjects: 8529

Group type: EXPERIMENTAL
Intervention: High-intensity imaging surveillance
Number of subjects: 8529

Group type: COMPARATOR
Intervention: Low-intensity imaging surveillance
Number of subjects: 8529

Group type: EXPERIMENTAL
Intervention: High-intensity CEA testing
Number of subjects: 8529

Group type: COMPARATOR
Intervention: Low-intensity CEA testing
Number of subjects: 8529
Study: 29800309

Group type: EXPERIMENTAL
Intervention: Live zoster VZVOka vaccine
Number of subjects: 44
Study: 29800971

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) for 8 cycles followed by individualized chemoradiotherapy (5 Gy × 5 with protons) with capecitabine for patients with resolution of vascular involvement; long-course chemoradiotherapy with fluorouracil or capecitabine for patients with persistent vascular involvement.
Number of subjects: 48
Study: 29801465

Group type: EXPERIMENTAL
Intervention: Erlotinib at 150 mg/day
Number of subjects: 62
Study: 29801483

Group type: EXPERIMENTAL
Intervention: Mass-treatment with praziquantel tablets as part of a Department of Health Mass-Treatment Campaign for schistosomiasis.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Focus Group Discussions and individual in-depth interviews to assess barriers to treatment.
Number of subjects: 6
Study: 29801516

Group type: EXPERIMENTAL
Intervention: Patients with delirium
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patients without delirium
Number of subjects: 50
Study: 29801520

Group type: EXPERIMENTAL
Intervention: G + A intervention (gambling intervention combined with problem drinking intervention)
Number of subjects: 280

Group type: COMPARATOR
Intervention: G-only intervention (targets only gambling issues)
Number of subjects: 280
Study: 29802016

Group type: EXPERIMENTAL
Intervention: Noninvasive FSS derived from coronary computed tomography angiography (CTA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Anatomic SYNTAX score (SS) calculated by CTA
Number of subjects: 77

Group type: COMPARATOR
Intervention: Invasive FSS
Number of subjects: 77
Study: 29802041

Group type: EXPERIMENTAL
Intervention: EXCLUDER device in narrow AOB cohort (NB)
Number of subjects: 1055

Group type: COMPARATOR
Intervention: EXCLUDER device in standard bifurcation cohort (SB)
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: EXCLUDER device in both cohorts
Number of subjects: 1055